ARTICLE | Company News
TolerRx Inc., Diabetogen deal
April 11, 2005 7:00 AM UTC
TolerRx acquired certain IP and material assets from Diabetogen related to anti-CD3 antibodies, including a patent application covering the therapeutic use of anti-CD3 antibodies for autoimmune diseas...